High-content CRISPR screening in tumor immunology

Front Immunol. 2022 Nov 21:13:1041451. doi: 10.3389/fimmu.2022.1041451. eCollection 2022.

Abstract

CRISPR screening is a powerful tool that links specific genetic alterations to corresponding phenotypes, thus allowing for high-throughput identification of novel gene functions. Pooled CRISPR screens have enabled discovery of innate and adaptive immune response regulators in the setting of viral infection and cancer. Emerging methods couple pooled CRISPR screens with parallel high-content readouts at the transcriptomic, epigenetic, proteomic, and optical levels. These approaches are illuminating cancer immune evasion mechanisms as well as nominating novel targets that augment T cell activation, increase T cell infiltration into tumors, and promote enhanced T cell cytotoxicity. This review details recent methodological advances in high-content CRISPR screens and highlights the impact this technology is having on tumor immunology.

Keywords: CRISPR screen; cancer immunotherapy; epigenetic readout; genomic imaging; proteomic readout; transcriptomic readout; tumor immunology.

Publication types

  • Review
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Clustered Regularly Interspaced Short Palindromic Repeats*
  • Epigenomics
  • Proteomics*